{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-018465","form_type":"8-K","ticker":"IDXG","cik":"0001054102","company_name":"INTERPACE BIOSCIENCES, INC.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.064726+00:00","generated_at":"2026-06-02T04:41:47.907424+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Interpace Q1 revenue $10.3M (+4% YoY); income from ops $0.6M; record test volume +10%","bullets":["Q1 net revenue $10.3M, up 4% YoY from $9.8M; test volume up 10% to record levels.","Income from continuing ops $0.6M vs $0.4M prior year; operating income $0.9M vs $0.7M.","Adjusted EBITDA $1.0M vs $1.2M prior year; gross margin 59% vs 61%.","Cash collections $10.2M; cash balance $2.8M at Mar 31, 2024, down from $5.6M due to $3.1M debt paydown.","Fifteenth consecutive quarter of YoY volume growth; CEO cites adoption of ThyGeNEXT, ThyraMIRv2, PancraGEN."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-018465","json":"https://secwatch.observer/filing/0001493152-24-018465.json","markdown":"https://secwatch.observer/filing/0001493152-24-018465.md","text":"https://secwatch.observer/filing/0001493152-24-018465.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1054102/000149315224018465/0001493152-24-018465-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1054102/000149315224018465/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T04:41:47.907424+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"948f25fed192c3f3b9d7fcadbe1ce4c6deb55226","claim":"INTERPACE BIOSCIENCES, INC. reported first quarter ended March 31, 2024 results: revenue $10.3 million, net income $0.6 million.","evidence_excerpt":"stated in such filing. --- EX-99.1 () --- EX-99.1 2 ex99-1.htm Exhibit 99.1 Interpace Biosciences Announces First Quarter 2024 Financial and Business Results ● Q1 Revenue of $10.3 million; a 4% increase year-over-year ● Q1 Test volume up 10% year over year to record levels PARSIPPANY, NJ, May 9, 2024 (GLOBE NEWSWIRE) — Interpace Biosciences, Inc. (“Interpace” or","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1054102/000149315224018465/0001493152-24-018465-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$10.3 million"},{"label":"Net income","value":"$0.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}